<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40971670</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1462-0332</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Sep</Month><Day>14</Day></PubDate></JournalIssue><Title>Rheumatology (Oxford, England)</Title><ISOAbbreviation>Rheumatology (Oxford)</ISOAbbreviation></Journal><ArticleTitle>Impact of dactylitis and enthesitis resolution on disease control in guselkumab-treated PsA patients with TNFi-IR: COSMOS post-hoc analysis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">keaf490</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/rheumatology/keaf490</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate guselkumab efficacy on dactylitis resolution (DR) and enthesitis resolution (ER), and their impact on subsequent disease control, in patients with active psoriatic arthritis (PsA) and prior inadequate response to tumour necrosis factor inhibitors (TNFi-IR).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In the Phase IIIb COSMOS trial, 285 adults with TNFi-IR PsA were randomized (2:1) to receive guselkumab 100&#x2009;mg or placebo at Week (W)0, W4, then every 8&#x2009;weeks until W44. The Dactylitis Severity Score (DSS) and Leeds Enthesitis Index (LEI) assessed dactylitis and enthesitis. This post-hoc analysis evaluated associations between W24&#x2009;DR/ER and W48 achievement of stringent disease control measures using logistic regression.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">At baseline, 103/285 (36.1%) patients had dactylitis (DSS&#x2009;&#x2265;&#x2009;1) and 190/285 (66.7%) had enthesitis (LEI&#x2009;&#x2265;&#x2009;1). Patients with dactylitis were more likely to have enthesitis, more joint (SJC/DAPSA) and skin involvement, higher PGA score, and lower BMI vs those without dactylitis. Patients with enthesitis were more likely to be female, and have dactylitis, more joints affected (SJC/TJC/DAPSA) and worse physical functioning (HAQ-DI/SF-36 PCS) vs those without enthesitis. Greater proportions of guselkumab- vs placebo-treated patients achieved DR/ER (W24: 44.8%/39.7% vs 25.0%/18.8%); rates increased through W48 among guselkumab-randomized patients (67.2%/55.6%). W24 resolution was associated with W48 achievement of stringent measures, including ACR50/70, DAPSA LDA/remission, PASI100, PASDAS LDA/VLDA, and MDA/VLDA (odds ratios: DR, 3.28-13.38; ER, 2.88-6.09).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Guselkumab treatment resulted in high DR/ER rates through W48 in TNFi-IR PsA patients. W24&#x2009;DR/ER was associated with W48 disease control, providing valuable insights for clinical decision-making based on W24 treatment responses.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2025. Published by Oxford University Press on behalf of the British Society for Rheumatology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Marzo-Ortega</LastName><ForeName>Helena</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-9683-3407</Identifier><AffiliationInfo><Affiliation>NIHR Leeds Biomedical Research Centre, The Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McInnes</LastName><ForeName>Iain B</ForeName><Initials>IB</Initials><Identifier Source="ORCID">0000-0002-6462-4280</Identifier><AffiliationInfo><Affiliation>MVLS College Office, University of Glasgow, Glasgow, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharaf</LastName><ForeName>Mohamed</ForeName><Initials>M</Initials><Identifier Source="ORCID">0009-0003-9847-2996</Identifier><AffiliationInfo><Affiliation>Johnson &amp; Johnson, Middle East TZ LLC, Dubai, UAE.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zabotti</LastName><ForeName>Alen</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-0573-464X</Identifier><AffiliationInfo><Affiliation>Rheumatology Institute, Azienda Sanitaria Universitaria del Friuli Centrale, Udine, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rampakakis</LastName><ForeName>Emmanouil</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-7427-8246</Identifier><AffiliationInfo><Affiliation>Department of Pediatrics, McGill University, Montreal, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>JSS Medical Research Inc., Scientific Affairs, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McGonagle</LastName><ForeName>Dennis</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-7715-8226</Identifier><AffiliationInfo><Affiliation>NIHR Leeds Biomedical Research Centre, The Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abogamal</LastName><ForeName>Ahmed</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-5236-424X</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology, Al Zahra Hospital, Dubai, UAE.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Al-Azhar Faculty of Medicine, Al-Azhar University, Cairo, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richette</LastName><ForeName>Pascal</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-2132-4074</Identifier><AffiliationInfo><Affiliation>Rheumatology Department, Lariboisi&#xe8;re Hospital, Paris Cit&#xe9; University, Paris, AP-HP, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schett</LastName><ForeName>Georg</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-8740-9615</Identifier><AffiliationInfo><Affiliation>Department of Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-Universit&#xe4;t Erlangen-N&#xfc;rnberg and Universit&#xe4;tsklinikum Erlangen, Erlangen, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Rheumatology (Oxford)</MedlineTA><NlmUniqueID>100883501</NlmUniqueID><ISSNLinking>1462-0324</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COSMOS</Keyword><Keyword MajorTopicYN="N">Guselkumab</Keyword><Keyword MajorTopicYN="N">clinical outcomes</Keyword><Keyword MajorTopicYN="N">dactylitis</Keyword><Keyword MajorTopicYN="N">enthesitis</Keyword><Keyword MajorTopicYN="N">psoriatic arthritis</Keyword><Keyword MajorTopicYN="N">resolution</Keyword><Keyword MajorTopicYN="N">tumour necrosis factor inhibitor</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>8</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>9</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>19</Day><Hour>18</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>19</Day><Hour>18</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>19</Day><Hour>15</Hour><Minute>34</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40971670</ArticleId><ArticleId IdType="doi">10.1093/rheumatology/keaf490</ArticleId><ArticleId IdType="pii">8253722</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>